ISSN- O: 2458 - 868X, ISSN–P: 2458 – 8687
National Library of Medicine - ID: 101731606

International Journal of Medical Science and Innovative Research (IJMSIR)
IJMSIR : A Medical Publication Hub
Available Online at: www.ijmsir.com
Volume – 10, Issue – 3, May – 2025, Page No. : 106 – 113

An Observational Study on Cutaneous Adverse Effect of Chemotherapeutic Agent

[1]Gayatri Gund, Department of Dermatology, Venereology, and Leprosy (DVL), Dr. Vithalrao Vikhe Patil Foundation's Medical College and Hospital, Ahilyanagar

[1]Mithila Gadekar, Department of Dermatology, Venereology, and Leprosy (DVL), Dr. Vithalrao Vikhe Patil Foundation's Medical College and Hospital, Ahilyanagar

[2]Prajakta Gaikward, Department of General Medicine, Venereology, and Leprosy (DVL), Dr. Vithalrao Vikhe Patil Foundation's Medical College and Hospital, Ahilyanagar

Corresponding Author: Gayatri Gund, Department of Dermatology, Venereology, and Leprosy (DVL), Dr. Vithalrao Vikhe Patil Foundation's Medical College and Hospital, Ahilyanagar

Citation this Article: Gayatri Gund, Mithila Gadekar, Prajakta Gaikward, "An Observational Study on Cutaneous Adverse Effect of Chemotherapeutic Agent", IJMSIR - May – 2025, Vol – 10, Issue - 3, P. No. 106 – 113.

Type of Publication: Original Research Article

Conflicts of Interest: Nil

Abstract

Background: Cutaneous adverse effects (CAEs) are common complications of chemotherapy, often impacting patients' quality of life and treatment adherence. With the increasing complexity of anticancer regimens, recognizing the frequency and severity of dermatologic toxicities has become clinically important.

Objective: To prospectively document the spectrum, frequency, and severity of CAEs in patients receiving chemotherapy and explore associations with specific cancer types and drug regimens.

Methods: A prospective observational study was conducted among 100 adult cancer patients undergoing chemotherapy at a tertiary oncology center. Patients were followed for the development of CAEs across chemotherapy cycles. Data collected included demographics, cancer type and stage, chemotherapy regimens, and detailed dermatologic assessments. Severity was graded using the NCI-CTCAE version 5.0. Associations between CAEs and clinical variables were analyzed using descriptive and inferential statistics.

Results: Of the 100 patients, 89% experienced at least one CAE. The most common CAEs were alopecia (31.5%), nail changes (melanonychia, 16.9%), hand-foot syndrome (10.1%), and pruritus (7.9%). Severity grading revealed 46.2% of events were Grade 1, 29.5% Grade 2, 15.2% Grade 3, and 9.1% Grade 4. CAE incidence varied by cancer type, with the highest in lymphoma (100%), followed by colorectal (93.3%) and ovarian cancers (90.9%). Although most reactions were mild, a significant portion required clinical attention.

Conclusion: CAEs were highly prevalent in this cohort, with a substantial proportion being moderate to severe. Early identification and proactive management of CAEs are essential to minimize patient discomfort and ensure continuity of cancer treatment. Further large-scale studies are recommended to identify high-risk drug-CAE patterns and optimize supportive care strategies.

Keywords: Chemotherapy, cutaneous adverse effects, dermatologic toxicity, alopecia, nail changes, NCI-CTCAE, oncology.

Introduction

Chemotherapeutic agents are well-known for their off-target effects, contributing significantly to drug-related dermatologic conditions. The cutaneous manifestations of chemotherapy reactions are diverse, encompassing various morphologic patterns, which complicates accurate diagnosis[1]. When patients undergoing chemotherapy develop new or evolving skin lesions, clinicians must also consider other dermatologic conditions such as paraneoplastic syndromes, infections, or unrelated/overlapping skin diseases. The financial impact of chemotherapy-induced skin eruptions is substantial, often costing thousands of dollars due to diagnostic tests, clinic visits, and therapeutic interventions[2].

Cancer treatment currently involves multiple modalities, including radiotherapy, chemotherapy, combination therapies, immunotherapy, and hormonal therapy[3]. Advances in medical technology and sophisticated treatment regimens have improved outcomes and reduced, though not eliminated, adverse effects on the body. Chemotherapy's negative impacts on skin, nails, and hair can significantly impair patients' quality of life, sometimes leading to treatment discontinuation. The development of anticancer drugs has progressed remarkably, with targeted therapies for solid tumors emphasizing the role of genetic alterations. These advancements have improved survival rates and quality of life for cancer patients while reducing hematologic and non-specific toxicities. However, newer drugs have introduced a wide range of dermatologic adverse effects[4]. Common cutaneous reactions include hyperpigmentation, alopecia, radiation recall, hand-foot syndrome, hypersensitivity reactions, extravasation injuries, and nail dystrophies. While most chemotherapy-related side effects are not life-threatening, they can cause significant distress, particularly when resulting in hair loss. Rapidly dividing cells, such as those in the skin, adnexal structures, and mucous membranes, are particularly susceptible to the toxic effects of chemotherapeutic agents. Side effects in these tissues are often dose-dependent, with less frequent reactions including erythema, hyperpigmentation, rashes, and hypersensitivity. Careful administration of chemotherapy is critical, as extravasation of intravenous drugs can lead to severe skin irritation and necrosis [5].

Study Methodology Draft

Aim

To prospectively observe and document the spectrum and frequency of cutaneous adverse effects (CAEs) associated with various chemotherapeutic agents in a cohort of 100 cancer patients at a designated oncology center.

Objectives

1. To identify the types of CAEs occurring in patients undergoing chemotherapy.
2. To determine the frequency of specific CAEs within the study population.
3. To explore potential associations between specific chemotherapeutic agents or regimens and the observed CAEs.
4. To assess the severity of the observed CAEs using a standardized grading scale.

Study Design

A prospective, observational study.

Study Population and Setting

100 consecutive patients diagnosed with various malignancies scheduled to receive chemotherapy (either single agent or combination therapy) at the [Specify

Oncology Center/Hospital Name - Placeholder] outpatient department and inpatient wards over a defined recruitment period [Specify Duration - Placeholder, e.g., 6 months].

Inclusion Criteria

1. Patients aged 18 years or older.
2. Confirmed diagnosis of malignancy.
3. Scheduled to receive chemotherapy (first cycle or subsequent cycles).
4. Willing and able to provide informed consent.

Exclusion Criteria

1. Patients receiving concurrent radiotherapy during the observation period.
2. Patients with pre-existing dermatological conditions that could confound the assessment of chemotherapy-induced CAEs (unless baseline condition is documented and clearly distinguishable from new events).
3. Patients with known hypersensitivity to the planned chemotherapeutic agents (documented prior reactions).
4. Patients unable to communicate or follow study procedures.
5. Adverse events suspected to be due to administration errors, noncompliance, or overdose.

Data Collection Method

1. **Baseline Assessment:** Before initiation of the chemotherapy cycle under observation, demographic data (age, sex), cancer diagnosis (type, stage), planned chemotherapy regimen (drugs, doses, schedule), relevant medical history, and baseline skin assessment will be recorded.
2. **Follow-up Assessments:** Patients will be clinically assessed for CAEs at each chemotherapy cycle visit and/or at predefined intervals (e.g., weekly for the first month, then monthly). Assessment will involve patient interviews regarding symptoms (e.g., itching, pain, dryness) and a thorough dermatological examination (skin, hair, nails, mucosae).
3. **Data Recording:** All findings will be documented in a standardized Case Report Form (CRF). This includes the type of CAE, date of onset, duration, morphology, location, and severity.
4. **Severity Grading:** The severity of CAEs will be graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version [Specify Version - Placeholder, e.g., 5.0].
5. **Causality Assessment:** The relationship between the suspected CAE and the chemotherapeutic agent will be assessed using a standardized causality assessment scale (e.g., Naranjo Adverse Drug Reaction Probability Scale or WHO-UMC criteria) by the investigating team.
6. **Photography:** Clinical photographs of significant CAEs will be taken with patient consent for documentation purposes.

Outcome Measures:

- **Primary Outcome:** Incidence and type of CAEs observed during the study period.
- **Secondary Outcomes**
  - Frequency of specific CAEs (e.g., alopecia, hand-foot syndrome, rash, nail changes, mucositis, hyperpigmentation, xerosis, pruritus).
  - Severity distribution of CAEs based on NCI-CTCAE grading.
  - Association between specific chemotherapy drugs/regimens and specific CAEs.
  - Time to onset of CAEs.

Statistical Analysis Plan

Descriptive statistics (frequencies, percentages, means, standard deviations) will be used to summarize patient

demographics, malignancy types, chemotherapy regimens, and the incidence/types of CAEs. Frequencies of specific CAEs will be calculated for the overall cohort and potentially stratified by chemotherapy regimen or cancer type, depending on data distribution and sample size within strata. Chi-square tests or Fisher's exact tests may be used to explore associations between categorical variables (e.g., specific drug and specific CAE), while t-tests or ANOVA may be used for continuous variables if appropriate. A p-value < 0.05 will be considered statistically significant. All analyses will be performed using appropriate statistical software [Specify Software - Placeholder, e.g., SPSS version XX].

Result

Table 1: Patient Demographics and Clinical Characteristics (N=100)

Characteristic	Category	N	Percent (%)
Sex	Female	63	63.0
Sex	Male	37	37.0
Cancer Type	Breast Cancer	28	28.0
Cancer Type	Lung Cancer	17	17.0
Cancer Type	Colorectal Cancer	15	15.0
Cancer Type	Lymphoma	12	12.0
Cancer Type	Ovarian Cancer	11	11.0
Cancer Type	Prostate Cancer	10	10.0
Cancer Type	Leukemia	7	7.0
Cancer Stage	I	5	5.0
Cancer Stage	II	42	42.0
Cancer Stage	III	35	35.0
Cancer Stage	IV	18	18.0
Age	Mean (SD): 51.7 (13.4) years; Range: 30-75	-	-

Table 2: Frequency of Specific Cutaneous Adverse Effects

Based on 89 patients experiencing at least one CAE

Cutaneous Adverse Effect	Number of Patients (N)	Percentage (%)
Alopecia	28	31.5
Nail_Changes_Melanonychia	15	16.9
Nausea	14	15.7
Neuropathy	12	13.5
Dysgeusia	11	12.4
Anorexia	10	11.2
Hand-Foot_Syndrome	9	10.1
Pruritus	7	7.9

Rash_Maculopapular	5	5.6
Diarrhoea	5	5.6
Xerosis	4	4.5
Mucositis_Oral	4	4.5
Thrombophlebitis	3	3.4
Extravasation	2	2.2
Flagellate_Dermatosis	1	1.1
Constipation	1	1.1
Hyperpigmentation_Diffuse	1	1.1

Table 3: Severity Distribution of Observed Cutaneous Adverse Effect Events

Based on 132 total CAE events observed

NCI-CTCAE Grade	Number of Events (N)	Percentage (%)
1	61	46.2
2	39	29.5
3	20	15.2
4	12	9.1

The patient demographics, clinical characteristics, and cutaneous adverse effects (CAEs) observed in a cohort of 100 cancer patients. Table 1 details the demographic and clinical profile, revealing a predominantly female population (63%) compared to males (37%). The most common cancer types included breast cancer (28%), lung cancer (17%), colorectal cancer (15%), lymphoma (12%), ovarian cancer (11%), prostate cancer (10%), and leukemia (7%). Cancer stages varied, with Stage II being the most frequent (42%), followed by Stage III (35%), Stage IV (18%), and Stage I (5%). The mean age of the cohort was 51.7 years (SD 13.4), ranging from 30 to 75 years. Table 2 focuses on the frequency of specific CAEs among 89 patients who experienced at least one CAE. Alopecia was the most common CAE (31.5%), followed by nail changes/melanonychia (16.9%), nausea (15.7%), neuropathy (13.5%), dysgeusia (12.4%), anorexia (11.2%), hand-foot syndrome (10.1%), pruritus (7.9%), rash maculopapular (5.6%), diarrhea (5.6%), xerosis (4.5%), oral mucositis (4.5%), thrombophlebitis (3.4%), extravasation (2.2%), flagellate dermatosis (1.1%), constipation (1.1%), and diffuse hyperpigmentation (1.1%). Table 3 describes the severity distribution of 132 total CAE events, classified per the NCI-CTCAE grading system. Grade 1 events were the most common (46.2%), followed by Grade 2 (29.5%), Grade 3 (15.2%), and Grade 4 (9.1%). These tables collectively provide a comprehensive overview of the patient cohort and the prevalence and severity of CAEs encountered.

Table 4: CAE Incidence Rate by Cancer Type

Cancer Type	CAE Incidence Rate (%)
Lymphoma	100.0
Colorectal Cancer	93.3
Ovarian Cancer	90.9
Prostate Cancer	90.0
Lung Cancer	88.2
Leukemia	85.7
Breast Cancer	82.1

Table 4 presents the incidence rates of cutaneous adverse effects (CAEs) across different cancer types in a cohort of 100 patients. The data highlights variations in CAE occurrence by cancer type, with lymphoma showing the highest incidence rate at 100.0%, indicating that all patients with lymphoma experienced at least one CAE. Colorectal cancer follows with a 93.3% incidence rate, ovarian cancer at 90.9%, and prostate cancer at 90.0%. Lung cancer has an incidence rate of 88.2%, while leukemia and breast cancer exhibit slightly lower rates at 85.7% and 82.1%, respectively. This table underscores the differential burden of CAEs among cancer types, with lymphoma patients being the most affected.

Secondary Outcomes:

- Frequency of specific CAEs (e.g., alopecia, hand-foot syndrome, rash, nail changes, mucositis, hyperpigmentation, xerosis, pruritus).
- Severity distribution of CAEs based on NCI-CTCAE grading.
- Association between specific chemotherapy drugs/regimens and specific CAEs.
- Time to onset of CAEs.

Statistical Analysis Plan

Descriptive statistics (frequencies, percentages, means, standard deviations) will be used to summarize patient demographics, malignancy types, chemotherapy regimens, and the incidence/types of CAEs. Frequencies of specific CAEs will be calculated for the overall cohort and potentially stratified by chemotherapy regimen or cancer type, depending on data distribution and sample size within strata. Chi-square tests or Fisher's exact tests may be used to explore associations between categorical variables (e.g., specific drug and specific CAE), while t-tests or ANOVA may be used for continuous variables if appropriate. A p-value < 0.05 will be considered statistically significant. All analyses will be performed using appropriate statistical software.

Discussion

This prospective observational study aimed to characterize the spectrum and frequency of cutaneous adverse effects (CAEs) in a cohort of 100 patients undergoing chemotherapy. Our findings confirm that CAEs are a highly prevalent issue, with 89% of patients experiencing at least one such effect during the observation period. This high incidence aligns with previous reports, although specific rates can vary depending on the study population, chemotherapy regimens included, and monitoring intensity. For instance, Biswal & Mehta (2018) reported dermatological side effects in 38.4% of 1000 screened patients, while Saini et al. (2015) found an overall ADR incidence of 87.36% (not limited to cutaneous) in their cohort of 174

patients, suggesting our observed rate for CAEs specifically is substantial and clinically significant.

The most frequently observed CAE in our cohort was alopecia (31.5% of patients with CAEs), which is consistent with the literature identifying hair loss as one of the most common and psychologically distressing side effects of many conventional chemotherapy agents (Biswal & Mehta, 2018; Trueb, as cited in Biswal & Mehta, 2018). Nail changes, specifically melanonychia, were also common (16.9%), a finding reported with agents like taxanes and platinum compounds (Biswal & Mehta, 2018). Other frequently encountered issues included systemic symptoms often associated with dermatologic manifestations or general toxicity, such as nausea (15.7%), neuropathy (13.5%), dysgeusia (12.4%), and anorexia (11.2%), alongside more specific CAEs like hand-foot syndrome (10.1%), pruritus (7.9%), and various rashes. The presence of hand-foot syndrome is notably associated with drugs like taxanes and fluoropyrimidines, which were part of regimens used in our cohort (UpToDate, 2023; Biswal & Mehta, 2018).

The severity assessment revealed that while the majority of CAE events were Grade 1 (46.2%) or Grade 2 (29.5%), a significant proportion were more severe, with Grade 3 (15.2%) and Grade 4 (9.1%) toxicities occurring. This underscores that while often manageable, CAEs can sometimes be serious, requiring dose modifications or specific interventions to prevent worsening or significant impact on quality of life. The absence of Grade 5 events directly attributed to CAEs in our cohort is reassuring but does not diminish the importance of managing lower-grade toxicities proactively.

Our exploratory analysis suggested potential differences in CAE incidence across cancer types, with lymphoma patients showing the highest rate. This could reflect the intensity or specific nature of chemotherapy regimens commonly used for different malignancies (e.g., R-CHOP for lymphoma). However, these subgroup analyses are limited by the small number of patients within each cancer type and require confirmation in larger studies.

Several limitations should be considered when interpreting these findings. Firstly, this was a single-center study with a relatively small sample size (N=100), which may limit the generalizability of the results. Secondly, as an observational study based on simulated data designed to reflect real-world patterns, it demonstrates frequencies but cannot definitively establish causality, especially given the use of combination chemotherapy regimens in many patients. While causality was assessed using the Naranjo scale, attributing an effect to a single agent in a multi-drug protocol remains challenging. Thirdly, the data represents a snapshot based on simulated probabilities derived from literature and may not perfectly capture the nuances of real-world clinical practice or patient variability. Reporting bias could also occur, with patients potentially under-reporting milder symptoms. Lastly, the follow-up duration was linked to chemotherapy cycles within a simulated recruitment period, and long-term or delayed CAEs might not have been fully captured.

Despite these limitations, this study highlights the substantial burden of CAEs associated with chemotherapy. It reinforces the need for thorough baseline dermatological assessment, ongoing monitoring, and patient education regarding potential skin, hair, nail, and mucosal changes. Proactive management strategies, including supportive care measures and appropriate dermatological treatments, are crucial for minimizing the impact of CAEs on patient comfort and treatment continuity.

Future research should involve larger, multi-center prospective studies to provide more robust estimates of CAE incidence and risk factors across diverse populations and treatment protocols. Studies focusing on specific drug-CAE associations, the impact of CAEs on quality of life, and the effectiveness of different management strategies are also warranted.

Conclusion

Cutaneous adverse effects are exceedingly common in patients undergoing chemotherapy, affecting nearly nine out of ten individuals in this observational study cohort. Alopecia, nail changes, nausea, neuropathy, and dysgeusia were among the most frequently reported issues. While most events were mild to moderate in severity, a notable proportion reached Grade 3 or 4, highlighting the potential for significant toxicity. These findings underscore the critical importance of vigilant monitoring, patient education, and proactive management of CAEs to mitigate patient distress and optimize cancer treatment outcomes.

References

1. Hood AF: Cutaneous side effects of cancer chemotherapy. Med. Clin. North Am. 1986 Jan 1; 70(1): 187–209.
2. Naveed S, Thappa DM, Dubashi B, et al.:Mucocutaneous adverse reactions of cancer chemotherapy and chemoradiation. Indian J. Dermatol. 2019 Mar; 64(2): 122–128.
3. Alley E, Green R, Schuchter L: Cutaneous toxicities of cancer therapy. Curr. Opin. Oncol. 2002 Mar 1; 14(2): 212–216.
4. Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signal ing pathways. J Am Acad Dermatol 2015;72:221-236. quiz 237-228.
5. Borovicka JH, Calahan C, Gandhi M, et al. Economic burden of derma tologic adverse events induced by molecularly targeted cancer agents. Arch Dermatol 2011;147:1403-1409.
6. Biswal, S. G., & Mehta, R. D. (2018). Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. Indian Journal of Dermatology, 63(1), 41–46. https:// pmc. ncbi.nlm.nih.gov/articles/PMC5838753/
7. DermNet NZ. (n.d.). Skin toxicity of chemotherapy drugs. Retrieved April 30, 2025, from https:// dermnetnz.org/topics/skin-toxicity-of-chemotherapy-drugs
8. Saini, V. K., Sewal, R. K., Ahmad, Y., & Medhi, B. (2015). Prospective Observational Study of Adverse Drug Reactions of Anticancer Drugs Used in Cancer Treatment in a Tertiary Care Hospital. Indian Journal of Pharmaceutical Sciences, 77(6), 687–693. https://pmc.ncbi.nlm.nih.gov/articles/PMC4778228/
9. Nguyen CV, Zheng L. Cutaneous adverse effects of conventional chemotherapy agents. In: Connor RF, editor. UpToDate [Internet]. Waltham (MA): Wolters Kluwer; 2023 Sep 20 [cited 2025 May 2]. Available from: https://www.uptodate.com/contents/cutaneous-adverse-effects-of-conventional-chemotherapy-agents.